Evidence map›Paper›PMID 35538376›Full record

ArticleAAPS PharmSciTech2022

Stiripentol Enteric Solid Dispersion-Loaded Effervescent Tablets: Enhanced Dissolution, Stability, and Absorption.

Ying Wang, Siyuan Xu, Ziyue Xiao, Yuxin Jiang, Qi Jiang, Jun Li, Wei He

Abstract read
PubMed Publisher
In one paragraph

Article in AAPS PharmSciTech, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Ying WangDepartment of Pharmaceutics, School of Pharmacy, China Pharmaceutical University, Nanjing, 211198, China.
Siyuan XuDepartment of Pharmaceutics, School of Pharmacy, China Pharmaceutical University, Nanjing, 211198, China.
Ziyue XiaoDepartment of Pharmaceutics, School of Pharmacy, China Pharmaceutical University, Nanjing, 211198, China.
Yuxin JiangDepartment of Pharmaceutics, School of Pharmacy, China Pharmaceutical University, Nanjing, 211198, China.
Qi JiangDepartment of Pharmaceutics, School of Pharmacy, China Pharmaceutical University, Nanjing, 211198, China.
Jun LiChildren's Hospital of Nanjing Medical University, Nanjing, China. lijunnu@163.com.
Wei HeDepartment of Pharmaceutics, School of Pharmacy, China Pharmaceutical University, Nanjing, 211198, China. weihe@cpu.edu.cn.ORCID http://orcid.org/0000-0003-3075-3831

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Due to poor solubility and stability in acid conditions, the gastrointestinal administration of stiripentol (STP) is still a significant challenge. This study aimed to explore the applicability of effervescent tablets compressed from STP-loaded enteric solid dispersions to improve the solubility and stability of the insoluble and acid-labile drug. STP-loaded solid dispersions (STP-SDs) and the effervescent tablets (STP-SD-ETs) were prepared using solvent evaporation and dry granulation technology, respectively, and their formulations were optimized. Then, STP-SDs were characterized regarding solid state, in vitro release, stability, etc. Results showed that enteric amorphous STP-SDs were successfully prepared and significantly improved the solubility and stability of STP. Moreover, compared with STP suspensions, the bioavailability of STP-SD-ETs was as high as 138.71%. Concomitantly, STP-SD-ETs significantly increased the intestinal absorption rate of STP. Overall, the oral preparation encompassing enteric solid dispersion combined with effervescent tablet technology possesses excellent performance in enhancing dissolution, anti-acid hydrolysis stability, and absorption of STP. Our work provides a promising method to improve the delivery of drugs with poor solubility and acid-labile stability.

Indexed as

DioxolanesBiological AvailabilitySolubilityTabletsDioxolanesstiripentolTabletsamorphouseffervescent tabletsepilepsysolid dispersionsstiripentol

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.